Delsona Therapeutics

Delsona Therapeutics is a private, clinical-stage company founded in 2021 and based in Cambridge, Massachusetts. It is developing the UltraNav platform, an ultrasound-based technology designed to overcome the significant challenge of the blood-brain barrier for drug delivery to the CNS. With a drug-agnostic approach, Delsona has initiated human trials in pediatric brain cancer and Alzheimer's disease, leveraging the strong scientific foundation of its founder, Dr. Elisa Konofagou. The company represents a convergence of biomedical engineering and therapeutics aimed at unlocking new treatments for neurological disorders.

UltraNav: A non-invasive, focused ultrasound-based platform that uses microbubbles to temporarily and locally open the blood-brain barrier (BBB) for targeted drug delivery to the central nervous system. It is drug-agnostic and does not require drug reformulation.

Delsona competes with other companies developing BBB penetration technologies, including other focused ultrasound approaches (e.g., by Insightec), receptor-mediated transport platforms (e.g., bioconjugates), and invasive methods like convection-enhanced delivery. Its non-invasive, localized, and drug-agnostic approach is a key differentiator.